

Inventors: Mazar and Jones  
Serial No.: 09/670,537  
Page No.: 4

**CURRENT STATUS OF ALL CLAIMS**

Claims 1 to 20. Withdrawn.

21. (Original) A uPA active site-targeting peptide compound that binds to the endosite and one or more exosites of (i) tcuPA or (ii) a fragment or subunit of tcuPA, which fragment or subunit retains the uPA (1) enzymatic endosite and (2) a uPAR-binding epitope, such that said peptide compound covalently modifies the endosite; said peptide compound including

(a) a detectable label,

(b) a therapeutic moiety, or

(c) a chelator that is optionally bound to a detectable label or a therapeutic moiety;

wherein the peptide compound localizes said chelator, detectable label or therapeutic moiety to the uPA active site.

22. (Currently amended) The peptide compound of claim 21 that has a structure defined by a general formula selected from the group consisting of:

(Label)-(Peptide Z)-(Xaa)<sub>2-6</sub>-(Lys,Arg)-(alkylating group);

(Therapeutic Moiety)-(Peptide Z)-(Xaa)<sub>2-6</sub>-(Lys,Arg)

Inventors: Mazar and Jones  
Serial No.: 09/670,537  
Page No.: 5

-(alkylating group);

~~(Chelator<sub>(empty)</sub>)~~ (Chelator)-Peptide Z)-  
(Xaa)<sub>2-6</sub>-

(Lys,Arg)-(alkylating group); and

(Label-Chelator)-(Peptide Z)-(Xaa)<sub>2-6</sub>-(Lys,Arg)-

(alkylating group),

wherein, in the formula, the Label is a detectable label, Xaa is any amino acid and Peptide Z is any peptide that binds to a surface exosite of uPA.

23. (Original) A molecule comprising the peptide compound of claims 21 or 22 bonded to the uPA endosite and to one or more exosites of

(a) uPA,

(b) tcuPA or

(c) a fragment or subunit of tcuPA that retain  
(i) the uPA enzymatic endosite and (ii) a uPAR-binding epitope.

24. Withdrawn.

25. (Currently amended) A method for detecting the presence of uPAR (i) on the surface of a cell, (ii) in a tissue,

Inventors: Mazar and Jones  
Serial No.: 09/670,537  
Page No.: 6

(iii) in an organ or (iv) in a biological sample, which cell, tissue, organ or sample is suspected of expressing uPAR due to a pathological state, comprising the steps of:

(a) contacting the cell, tissue, organ or sample with the molecule or composition of any one of claims ~~13, 16,~~ 21 or 22

(b) detecting the presence of the label associated with the cell, tissue, organ or sample.

26. Withdrawn.

27. (Original) The method of claim 25 wherein the contacting and the detecting are *in vitro*.

28. Withdrawn.

29. (Original) The method of claim 25 wherein the contacting is *in vivo* and the detecting is *in vitro*.

30. Withdrawn.

31. (Original) The method of claim 25, wherein the contacting and the detecting are *in vivo* .

32 to 34. Withdrawn.

Inventors: Mazar and Jones  
Serial No.: 09/670,537  
Page No.: 7

35. (Currently amended) A diagnostic or therapeutic ~~uPAR-targeting~~ uPA active site-targeting peptide pharmaceutical composition comprising:

(a) an effective amount of the peptide of claim 21 to which is bound directly or indirectly a detectable label or therapeutically active moiety; and

(b) a pharmaceutically acceptable carrier.

36. (Currently amended) A diagnostic or therapeutic ~~uPAR-targeting~~ uPA active site-targeting pharmaceutical composition comprising:

(a) an effective amount of the peptide of claim 23 to which is bound directly or indirectly a detectable label or therapeutically active moiety; and

(b) a pharmaceutically acceptable carrier.

37. Withdrawn.

38. (Original) The pharmaceutical composition of claim 35 in a form suitable for injection.

39. (Original) The pharmaceutical composition of claim 36 in a form suitable for injection.

40. Withdrawn.

Inventors: Mazar and Jones  
Serial No.: 09/670,537  
Page No.: 8

41. (Original) The therapeutic pharmaceutical composition of claim 35 wherein the therapeutically active moiety is a radionuclide.

42. Withdrawn.

43. (Original) The therapeutic pharmaceutical composition of claim 41, wherein the radionuclide is selected from the group consisting of  $^{47}\text{Sc}$ ,  $^{67}\text{Cu}$ ,  $^{90}\text{Y}$ ,  $^{109}\text{Pd}$ ,  $^{125}\text{I}$ ,  $^{131}\text{I}$ ,  $^{186}\text{Re}$ ,  $^{188}\text{Re}$ ,  $^{199}\text{Au}$ ,  $^{211}\text{At}$ ,  $^{212}\text{Pb}$  and  $^{217}\text{Bi}$ .

44. Withdrawn.

45. (Original) A method for inhibiting cell migration, cell invasion, cell proliferation or angiogenesis, or for inducing apoptosis, comprising contacting cells associated with undesired cell migration, invasion, proliferation or angiogenesis with an effective amount of a therapeutic pharmaceutical composition according to claim 35.

46. Withdrawn.

47. (Original) A method for inhibiting the invasiveness of tumor cells comprising contacting the cells with an effective amount of a therapeutic pharmaceutical composition according to claim 35.

48. Withdrawn.

Inventors: Mazar and Jones  
Serial No.: 09/670,537  
Page No.: 9

49. (Original) A method for treating a subject having a disease or condition associated with undesired cell migration, invasion, proliferation, or angiogenesis, comprising administering to the subject an effective amount of a pharmaceutical composition according to claim 35.